Preprint
Phase I Pharmacokinetic Study of Single Agent Trametinib in Patients With Advanced Cancer and Hepatic Dysfunction
Abstract
Background
Trametinib is an oral MEK 1/2 inhibitor, with a single agent recommended phase 2 dose (RP2D) of 2 mg daily (QD). This study was designed to evaluate RP2D, maximum tolerated dose (MTD), and pharmacokinetic (PK) profile of trametinib in patients with advanced solid tumors who had various degrees of hepatic dysfunction (HD).
Authors
Voon PJ; Chen EX; Chen HX; Lockhart AC; Sahebjam S; Kelly K; Vaishampayan UN; Subbiah V; Razak AR; Renouf DJ
DOI
10.21203/rs.3.rs-1041332/v1
Preprint server
Research Square